Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys
- PMID: 8689042
- DOI: 10.1177/096368979600500220
Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys
Abstract
Transplantation of fetal dopamine neurons to the adult striatum potentially offers a means to reverse the striatal dopamine deficiency that characterizes Parkinson's disease. Many investigations in rodents have supported the hope that neural grafting may be a useful treatment for parkinsonism. However, clinical studies have generally produced more modest improvements in motor abnormalities than observed in lower species. It is possible that the number of fetal dopamine neurons that survive transplantation is insufficient to restore dopaminergic innervation of the large human striatum to a level where striking recovery is obtained. In fact, there has been no quantitative study of graft outgrowth to indicate what portion of the dopamine-depleted striatum might be reinnervated with present techniques. Furthermore, it has been speculated that regeneration of the host dopamine system in response to the implantation surgery may play an important role in the beneficial effects of neural grafting in primates. The present study used nine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonian monkeys to investigate these issues. Sham implantation procedures produced no increase in either dopamine transporter density (measured by quantitative autoradiography) or tissue dopamine concentration (measured by HPLC) in the striatum of MPTP-treated monkeys. In sham-grafted and nonimplanted MPTP-treated monkeys, the striatal dopamine concentration was reduced by 99%, based on analysis of 16 sampled sites in the caudate nucleus and putamen of each monkey. No behavioral recovery was seen in the sham-grafted and nonimplanted MPTP-treated groups. In contrast, transplantation of fetal dopamine neurons to the caudate nucleus or putamen of MPTP-treated monkeys resulted in a significant elevation of dopamine transporter density and dopamine levels in the grafted striatal nucleus. Each grafted MPTP-treated monkey received ventral mesencephalon dopamine neurons from one donor harvested during putative neurogenesis. Donor ventral mesencephalon was divided equally and implanted into six sites either in the caudate nucleus or putamen. One graft site in each monkey was examined by dopamine transporter autoradiography. In sections in which graft fibers were present, a mean of one-third of the volume of the grafted nucleus was occupied by an elevated density of dopamine transporters. This increase in dopamine transporter density was defined to be at least 5-10% of the control density. However, full behavioral recovery was not observed in the grafted MPTP-treated group. These data provide no support for the hypothesis that regeneration of the host dopamine system occurs in response to a sham implantation procedure in severely parkinsonian monkeys. The current study illustrates the power of the applied techniques for delineating the relationship between the level of host dopamine depletion, the extent of graft-induced dopaminergic restoration, and behavioral recovery.
Similar articles
-
Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study.Brain Res. 1998 Jun 8;795(1-2):55-62. doi: 10.1016/s0006-8993(98)00252-2. Brain Res. 1998. PMID: 9622593
-
Early gestational mesencephalon grafts, but not later gestational mesencephalon, cerebellum or sham grafts, increase dopamine in caudate nucleus of MPTP-treated monkeys.Neuroscience. 1996 May;72(2):477-84. doi: 10.1016/0306-4522(95)00564-1. Neuroscience. 1996. PMID: 8737417
-
Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys.Cell Transplant. 1995 Jan-Feb;4(1):13-26. doi: 10.1177/096368979500400105. Cell Transplant. 1995. PMID: 7728327
-
Update on fetal transplantation: the Swedish experience.Mov Disord. 1998;13 Suppl 1:83-7. Mov Disord. 1998. PMID: 9613723 Review.
-
Combined cell-based therapy strategies for the treatment of Parkinson's disease: focus on mesenchymal stromal cells.Neural Regen Res. 2023 Mar;18(3):478-484. doi: 10.4103/1673-5374.350193. Neural Regen Res. 2023. PMID: 36018150 Free PMC article. Review.
Cited by
-
Endometrial stem cell transplantation in MPTP- exposed primates: an alternative cell source for treatment of Parkinson's disease.J Cell Mol Med. 2015 Jan;19(1):249-56. doi: 10.1111/jcmm.12433. Epub 2014 Oct 6. J Cell Mol Med. 2015. PMID: 25283241 Free PMC article.
-
The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Brain Res Bull. 2012 Jul 1;88(4):320-31. doi: 10.1016/j.brainresbull.2012.03.001. Epub 2012 Apr 11. Brain Res Bull. 2012. PMID: 22521427 Free PMC article. Review.
-
Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration.Neuropharmacology. 2012 Mar;62(3):1442-52. doi: 10.1016/j.neuropharm.2011.08.026. Epub 2011 Aug 23. Neuropharmacology. 2012. PMID: 21875607 Free PMC article.
-
Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives.Primate Biol. 2017 Oct 11;4(2):185-213. doi: 10.5194/pb-4-185-2017. eCollection 2017. Primate Biol. 2017. PMID: 32110706 Free PMC article. Review.
-
Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model.J Cell Mol Med. 2011 Apr;15(4):747-55. doi: 10.1111/j.1582-4934.2010.01068.x. J Cell Mol Med. 2011. PMID: 20406327 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources